144 related articles for article (PubMed ID: 38574488)
1. Chronic Myeloid Leukemia in Renal Transplantation Patients in the Era of Tyrosine Kinase Inhibitors: A Case Report and Review of the Literature.
Murt A; Bayram B; Yılmaz U; Seyahi N; Eşkazan AE
Nephron; 2024 Apr; ():1-6. PubMed ID: 38574488
[TBL] [Abstract][Full Text] [Related]
2. A Case Report of Successful Kidney Transplantation in a Patient With Chronic Myelogenous Leukemia (CML) Who Has Been in Remission for 15 Years on Imatinib.
Tokumoto T; Setoguchi K; Osaka A; Ikezoe E; Tsujioka H; Hasegawa K; Inoue M; Nirazuka A; Iwahata T; Inoue Y; Saito K
Transplant Proc; 2023 May; 55(4):1074-1077. PubMed ID: 37147192
[TBL] [Abstract][Full Text] [Related]
3. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives for the treatment of chronic myeloid leukemia.
Aladağ E; Haznedaroğlu İC
Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
[TBL] [Abstract][Full Text] [Related]
5. Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib.
Thiem U; Buxhofer-Ausch V; Kranewitter W; Webersinke G; Enkner W; Cejka D
Am J Transplant; 2021 Jan; 21(1):405-409. PubMed ID: 32654389
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
7. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
Haddad FG; Kantarjian H
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394773
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of Chronic Myeloid Leukemia With Dasatinib After Kidney Transplantation: A Case Report.
Yamane H; Ide K; Tanaka A; Hashimoto S; Nagoshi H; Tahara H; Ohira M; Seidakhmetov A; Marlen D; Tanaka Y; Ohdan H
Transplant Proc; 2020 Mar; 52(2):600-603. PubMed ID: 31733802
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia in solid organ transplant patients: a case series.
Amitai I; Abulafia AS; Raanani P; Lipton JH
Int J Hematol; 2021 Feb; 113(2):214-218. PubMed ID: 33021721
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Cha SH; Kim K; Song YK
Acta Oncol; 2023 Dec; 62(12):1767-1774. PubMed ID: 37787749
[TBL] [Abstract][Full Text] [Related]
11. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid Leukemia.
Sönmez Ö; Özgür Yurttaş N; İhtiyaroğlu İ; Çakır HM; Atlı Z; Elverdi T; Salihoğlu A; Seyahi N; Ar MC; Öngören Ş; Başlar Z; Soysal T; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):232-239. PubMed ID: 38281820
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
13. A Case Report of Kidney Transplantation in a Patient With Pre-existing Chronic Myeloid Leukemia: The Role of Achieving Molecular Response and Treatment-Free Remission.
Pinlac V; Bonifacio L
Transplant Proc; 2024 Apr; 56(3):738-741. PubMed ID: 38538381
[TBL] [Abstract][Full Text] [Related]
14. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
15. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
Takahashi N; Kameoka Y; Onizuka M; Onishi Y; Takahashi F; Dan T; Miyata T; Ando K; Harigae H
Cancer Med; 2023 Feb; 12(4):4250-4258. PubMed ID: 36151699
[TBL] [Abstract][Full Text] [Related]
16. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system.
Malkan UY; Haznedaroglu IC
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5493-5506. PubMed ID: 37401285
[TBL] [Abstract][Full Text] [Related]
18. Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment.
Bettoni da Cunha-Riehm C; Hildebrand V; Nathrath M; Metzler M; Suttorp M
Front Immunol; 2020; 11():628. PubMed ID: 32362894
[TBL] [Abstract][Full Text] [Related]
19. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.
Heibl S; Buxhofer-Ausch V; Schmidt S; Webersinke G; Lion T; Piringer G; Kuehr T; Wolf D; Melchardt T; Greil R; Thaler J
Hematol Oncol; 2020 Dec; 38(5):792-798. PubMed ID: 32757230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
